Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease [PDF]
Antithyroid drugs have been reported to reduce the expression of HLA-DR in thyrocytes in Graves' disease, but only circumstantial evidence has been provided about their in vivo immunologic effects.
Zantut-Wittmann, DE +8 more
core +1 more source
Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves' disease [PDF]
Background: The aim of this study was to compare long-term mortality, morbidity, and cumulative healthcare costs between antithyroid drugs, radioactive iodine, and surgical treatment for patients with persistent or relapsed Graves' disease.
Liu, XD +7 more
core +1 more source
A case of thyrotoxic periodic paralysis as initial manifestation of Graves' disease in a 16-year-old Korean adolescent [PDF]
Thyrotoxic periodic paralysis (TPP) is a rare complication of hyperthyroidism, with recurrent muscle paralysis and hypokalemia that are caused by an intracellular shift of potassium.
Se Yong Jung +5 more
doaj +1 more source
Differences in Outcomes and Complications in Graves’ Disease in Patients Treated with Antithyroid Drugs, Thyroidectomy, and Radioiodine Ablation [PDF]
Background: Graves’ Disease is an autoimmune disease that is the most common cause of hyperthyroidism in the United States. Treatment options include antithyroid drugs, radioactive iodine ablation, and thyroidectomy.
Shaffer, David
core
A Crystalline and Thermally Stable Selenocysteine Selenenic Acid
The long‐sought catalytic intermediate of selenoproteins, selenocysteine selenenic acid (Sec–SeOH), is isolated for the first time at ambient temperature. A bioinspired selenopeptide sequence encapsulated within a protective molecular cradle and an oxidant‐free route from selenenyl iodide (Sec–SeI) enable the isolation of Sec–SeOH. Contrary to the long‐
Ryosuke Masuda, Satoru Kuwano, Kei Goto
wiley +1 more source
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study [PDF]
Objective. To test whether antineutrophil cytoplasmic antibodies (ANCA) and ANCA-associated vasculitis (AAV) are not only induced during treatment with antithyroid drugs, but can also become evident when medication has been ceased, possibly after years ...
Links, TP +4 more
core +1 more source
Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism
Objective: Graves' disease is the commonest cause of hyperthyroidism in populations with sufficient dietary iodine intake. Anti-thyroid drugs (ATD) are often used as the initial treatment for Graves' hyperthyroidism, however there is a paucity of data ...
Ali Abbara +22 more
doaj +1 more source
Thyroid diseases are common among women of reproductive age and may be related to childhood cancer, but the evidence is inconsistent. This study of childhood cancer with maternal thyroid diseases and medication use in a population‐based case‐control study using Danish registries found positive associations between maternal goiter and overall cancer ...
Chuanjie Deng +5 more
wiley +1 more source
Fetal Goiter: A Case Presentation
The association of hyperthyroidism and pregnancy is a rare but potentially serious condition that occurs in 0.2% of pregnancies (1). However, during pregnancy, hyperthyroidism is frequently seen as a maternal endocrine disease; Graves' disease is the ...
Mehmet Uludoğan +4 more
doaj +2 more sources

